Current Report Filing (8-k)
June 04 2021 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 3, 2021
ADVAXIS,
INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36138
|
|
02-0563870
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
9
Deer Park Drive, Suite K-1
Monmouth
Junction, NJ
|
08852
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (609) 452-9813
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, par value $0.001 per share
|
|
ADXS
|
|
Nasdaq
Capital Market
|
Preferred
Stock Purchase Right
|
|
-
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On
June 3, 2021, at the 2021 Annual Meeting of Stockholders of Advaxis, Inc. (the “Company”), the Company’s stockholders
approved an Amendment to the Advaxis, Inc. 2015 Incentive Plan (the “Amendment”), which was previously approved, subject
to stockholder approval, by the Board of Directors (the “Board”) of the Company on February 11, 2021. The Amendment increases
the existing per-participant annual award limitations under the Company’s 2015 Incentive Plan to those set forth below:
|
●
|
|
Options.
The maximum number of options granted under the 2015 Incentive Plan in any calendar year to any one participant shall be for 1,000,000
shares.
|
|
|
|
|
|
●
|
|
Stock
Appreciation Rights. The maximum number of stock appreciation rights granted under the 2015 Incentive Plan in any calendar year to
any one participant shall be with respect to 750,000 shares.
|
|
|
|
|
|
●
|
|
Performance
Awards. With respect to any calendar year (i) the maximum amount that may be paid to any one participant for performance awards payable
in cash or property other than shares shall be $10,000,000, and (ii) the maximum number of shares that may be paid to any one participant
for performance awards payable in stock shall be 1,000,000 shares. For purposes of applying these limits in the case of multi-year
performance periods, the amount of cash or property or number of shares deemed paid with respect to any calendar year is the total
amount payable or shares earned for the performance period divided by the number of calendar years in the performance period.
|
|
|
|
|
|
●
|
|
Awards
to Non-Employee Directors. The maximum aggregate number of shares associated with any award granted under the 2015 Incentive Plan
in any calendar year to any of the Company’s non-employee directors shall be 200,000 shares.
|
Except
for the increases to the existing annual award limitations under the 2015 Incentive Plan, as described above, the Amendment does not
have any effect on the other provisions of the 2015 Incentive Plan.
The
foregoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text
of the Amendment which is attached to this Current Report on Form 8-K as Exhibit 10.1.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
June
4, 2021
|
ADVAXIS, INC.
|
|
|
|
|
By:
|
/s/
Kenneth A. Berlin
|
|
Name:
|
Kenneth
A. Berlin
|
|
Title:
|
President
and Chief Executive Officer and Interim Chief Financial Officer
|
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024